FDA recently announced the issuance of the first voucher awarded under its restored Rare Pediatric Disease (RPD) Priority Review Voucher Program for a drug that was approved after the program’s previous sunset. The Consolidated Appropriations Act, signed into law on February 3, 2026, reintroduced voucher availability for RPD-designated drugs and created a safety net for designations made when vouchers were not immediately available.
